The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| NAGE | +120.7% | +57.05% | +9.44% | -33% |
| S&P | +16.9% | +95.99% | +14.39% | +417% |
Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.
The company lost a key patent infringement lawsuit but plans to appeal the court decision.
The company's flagship product was launched in Walmart stores across the U.S.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $31.12M | 36.8% |
| Gross Profit | $20.23M | 47.7% |
| Gross Margin | 65.00% | 4.8% |
| Market Cap | $1.14B | 450.4% |
| Market Cap / Employee | $10.91M | 0.0% |
| Employees | 104 | -1.9% |
| Net Income | $3.61M | 24160.0% |
| EBITDA | $3.38M | 233.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $60.47M | 116.9% |
| Accounts Receivable | $9.66M | 123.6% |
| Inventory | 14.4 | 25.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $2.33M | 8.9% |
| Short Term Debt | $0.96M | -2.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 24.36% | 26.9% |
| Return On Invested Capital | -47.83% | 33.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $1.11M | 501.8% |
| Operating Free Cash Flow | $1.24M | 571.2% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 193.12 | 50.38 | 39.95 | 67.12 | - |
| Price to Book | 8.07 | 11.74 | 11.58 | 20.42 | 188.17% |
| Price to Sales | 3.10 | 4.35 | 5.32 | 10.69 | 343.33% |
| Price to Tangible Book Value | 8.17 | 11.87 | 11.67 | 20.54 | 185.12% |
| Price to Free Cash Flow TTM | 71.43 | 36.43 | 29.46 | 59.52 | -74.32% |
| Enterprise Value to EBITDA | 80.29 | 52.39 | 105.14 | 350.65 | 95.88% |
| Free Cash Flow Yield | 1.4% | 2.7% | 3.4% | 1.7% | 289.43% |
| Return on Equity | 4.8% | 22.9% | 33.5% | 37.4% | -899.50% |
| Total Debt | $2.90M | $2.65M | $3.52M | $3.29M | 5.38% |
CDXC earnings call for the period ending September 30, 2021.
CDXC earnings call for the period ending December 31, 2020.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
